WOONSOCKET, R.I., June 30, 2025 /PRNewswire/ -- CVS Health® (NYSE: CVS) will hold a conference call with analysts and investors on Thursday, July 31st, 2025, at 8:00 a.m. ET to discuss second quarter 2025 financial results.
An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year.
About CVS Health
CVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of March 31, 2025, the Company had more than 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics, a leading pharmacy benefits manager with approximately 88 million plan members, and a dedicated senior pharmacy care business serving more than 800,000 patients per year. The Company also serves an estimated more than 37 million people through traditional, voluntary and consumer-directed health insurance products and related services, including highly rated Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.
Media contact
Ethan Slavin
860-273-6095
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor contact
Larry McGrath
800-201-0938
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$67.26 |
Daily Change: | 0.66 0.99 |
Daily Volume: | 2,234,755 |
Market Cap: | US$84.750B |
February 17, 2025 February 12, 2025 November 19, 2024 November 18, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load